Analgesic drugs don’t reduce ovarian cancer risk

	Tweet

The regular use of over-the-counter analgesic drugs, such as aspirin and ibuprofen, does not appear to reduce the risk of ovarian cancer, according to findings published in the American Journal of Epidemiology.

It has been suggested that inflammation may be involved in the development of ovarian cancer, “possibly acting in concert with ovulation,” Dr. Mary Anne Rossing, of Fred Hutchinson Cancer Research Center, Seattle, and colleagues write. Drugs with anti-inflammatory effects, such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), have been suggested as possible treatment to prevent the development of ovarian cancer.

In a population-based study, the researchers evaluated the analgesic use in 812 women diagnosed with ovarian cancer and in 1313 “control” subjects who acted as a comparison group. In-person interviews were used to assess analgesic use, excluding use within the previous year. 

A total of 1007 women (47 percent) reported previous use of acetaminophen, aspirin, ibuprofen, or other NSAIDs on 5 or more days per month for at least 6 consecutive months.

In contrast, an association was observed between acetaminophen and aspirin and a slightly increased risk of ovarian cancer. The increased risk was found mainly in women who had used the drugs for more than 10 years, with an increased risk of 80 percent for acetaminophen and 60 percent for aspirin.

However, among women who used aspirin, those who began regular use within the previous 5 years had a reduced risk of ovarian cancer of about 40 percent, as did those who took aspirin for heart disease prevention at about 30 percent.

“These results, in the context of prior findings, do not provide compelling evidence of a true increase in risk of ovarian cancer among women who use these drugs,” Rossing and colleagues conclude. “However, they add to the weight of evidence that, in the aggregate, provides little support for the use of analgesic drugs as chemoprevention for this disease.”

SOURCE: American Journal of Epidemiology, June 15, 2008.

RELATED STORIES:
Possible way to treat ovarian cancer reported   Cancer-Reducing Benefits of Preventive Surgery May Be Specific to Gene Mutation   Short-term OC use cuts ovarian cancer risk   Study Finds Aspirin, Vitamin E Don’t Prevent Cancer   DNA repair pathway score for predicting chemotherapy response in ovarian cancer patients   Physical activity does not ward off ovarian cancer   Experimental Drug Boosts Survival Time For Recurrent Ovarian Cancer   Ovarian Cancer Screening Not Catching Early Disease   New treatment to overpower drug resistance in ovarian cancer   Goodness of milk ‘offset by ovarian cancer risk’   Israeli woman gives birth after ovary transplant   Platypus Link to Ovarian Cancer   Ovarian cancer subtypes are different diseases: Implications for biomarker studies   Trial of Topotecan following Carboplatin and Paclitaxel in treatment of ovarian cancer   Clues to Ovarian Cancer’s Deadly Secrets   Bloating, pain may precede ovarian cancer   2 reproductive factors are important predictors of death from ovarian cancer   Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward   Soy may lessen risk of endometrial, ovarian cancers   Removal of Ovaries Decreases Cancer Risk for Women at High-Risk   Roche upbeat on Avastin in ovarian cancer   Abdominal chemotherapy boosts survival in ovarian cancer patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]